October 20, 2017 — Median Technologies announced that it will participate in The Liver Meeting, the annual meeting of the Association for the Study of Liver Diseases (AASLD) Oct. 20-24 in Washington, D.C. The company's scientific and business team will demonstrate Median's imaging phenomics platform iBiopsy.
iBiopsy is Median's investigational platform designed to acquire, index and analyze imaging phenomics, decoding disease biomarkers from standard medical images. The system provides insights into the development of novel therapies and individualized treatment strategies. The first application of iBiopsy is for the assessment of nonalcoholic steatohepatitis (NASH), a liver disease which is dramatically increasing in prevalence in all parts of the world.
iBiopsy is also the backbone of Median's development efforts and combines the latest advances in artificial intelligence (AI) and big data predictive analytics to harness the power of imaging phenomics.
For more information: www.mediantechnologies.com